Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
NCT02967770
Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
Phase: Phase 2
Role: Collaborator
Start: Nov 30, 2016
Completion: Aug 30, 2018